Series B · Biotech
Leyden Laboratories: Series B
Develops broadly protective antibody-based nasal sprays to prevent infection by influenza and other respiratory viruses
Funding history
Series B · This round€40M
Loading rounds…
Develops broadly protective antibody-based nasal sprays to prevent infection by influenza and other respiratory viruses